Study Assessing the Safety and Therapeutic Effect of Buprenorphine in MDD Patients
A Single Center, Open Label, Dose-titration, add-on Study Assessing the Feasibility, Safety and Therapeutic Effect of Buprenorphine in Adult Patients With Diagnosis of Major Depression.
The primary objective of this study is to assess the therapeutic effect of Buprenorphine in MDD population.
The secondary objectives of this study are to assess the therapeutic effect, the feasibility and safety of buprenorphine in a MDD population.
研究概览
研究类型
注册 (预期的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Hod-Hasharon、以色列
- Shalvata Medical Health Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Outpatients and inpatients
- Men and women 18-68 years of age.
- Primary DSM-IV diagnosis of Major Depression, single or recurrent episode confirmed by the Structured Clinical Interview for the DSM-IV (SCID-IV), with the additional requirements of a current episode ≥4 weeks and CGI-S ≥4.
- Total HDRS-21 ≥20 and Item 1 score ≥2 at the screening visit.
- The patient did not respond to at least one antidepressant medication given for an accepted dose and duration.
- If currently taking Benzodiazepines, the patient must be clinically appropriate to discontinue treatment with those agents, and able to tolerate no benzodiazepines during the study period.
- Capable and willing to provide informed consent
- Able to adhere to the treatment schedule.
Exclusion Criteria:
- Depression secondary to a general medical condition.
- History of substance abuse or dependence within the past 6 month (except nicotine and caffeine).
- All antidepressant medications, must have been in stable dosage for at least 6 weeks prior to entry into the study, with no anticipation of change over the duration of the study.
- Use of any medication(s) listed on the Excluded medication list within the time that mansion for each medication on the list.
- Any psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features • Bipolar disorder • Eating disorder
- Presence (within 12 months of baseline) of a personality disorder (such as antisocial, schizotypal, histrionic, borderline, narcissistic) as assessed by the investigator to be primary, causing a higher degree of distress or impairment than MDD.
- Use of a Monoamine Oxidase Inhibitor (MAOI) within 2 weeks of the screening visit
- Use of a CYP3A4 Inhibitors and CYP3A4 Inducers within 2 weeks of screening visit.
- Present suicidal risk as assessed by the investigator or significant suicide risk based on HDRS-21 item 3 score of 3 or 4 or a history of attempted suicide in the last 6 month
- Known or suspected pregnancy
- Women who are breast-feeding
- Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse.
- Patients with severe respiratory insufficiency or asthma - anticipation require examination of pulmonologist.
- Patients with severe hepatic or renal insufficiency.
- Patients with history of head injury, increased intracranial pressure, hypotension, prostatic hypertrophy or urethral stenosis- anticipation require examination of neurologist.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:丁丙诺啡
|
In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit. From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
The primary objective of this study is to assess the therapeutic effect of Buprenorphine in MDD population.
大体时间:from baseline to day 42 [end of Buprenorphine treatment]
|
from baseline to day 42 [end of Buprenorphine treatment]
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
The secondary objectives of this study are to assess the therapeutic effect, the feasibility and safety of buprenorphine in a MDD population.
大体时间:from baseline to day 42 [end of Buprenorphine treatment]
|
from baseline to day 42 [end of Buprenorphine treatment]
|
合作者和调查者
调查人员
- 首席研究员:ziv carmel, M.D.、Shalvata Medical Health Center
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.